Correlation of Genetic Polymorphism of CYP3A5 to Vincristine Efficacy and Toxicity in Rhabdomyosarcoma in Pediatric Egyptian Cancer Patients / (Record no. 173058)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07580namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250828103725.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250714s2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.1 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.M.Sc.2024.No.C. |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Norhan Esmail Abdel Aziz Shalaby, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Correlation of Genetic Polymorphism of CYP3A5 to Vincristine Efficacy and Toxicity in Rhabdomyosarcoma in Pediatric Egyptian Cancer Patients / |
| Statement of responsibility, etc. | By Norhan Esmail Abdel Aziz Shalaby; Under Supervision Of Prof. Dr. Osama Badary, Prof.Dr. Hala Fahmy Zaki, Assoc.Prof.Dr. Mona Magdy Saber. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | علاقة تعدد الأشكال الوراثية للـ CYP3A5 بكفاءة عقار الفينكريستين وسميته في الساركوما العضلية عند الأطفال المصريين المرضي بالسرطان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 107 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc.)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 92-103. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Rhabdomyosarcoma (RMS) is a rare cancer that develops in soft tissue, particularly skeletal muscle tissue and occasionally hollow organs like the bladder or uterus. Rhabdomyosarcoma is an uncommon illness that accounts for 3% of all pediatric malignancies. However, RMS is the most frequent soft tissue sarcoma in children and adolescents, accounting for half of all soft tissue sarcomas in people under the age of 20. Rhabdomyosarcoma is categorized into five histological subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Most RMS patients are treated with a multimodal strategy that includes chemotherapy, surgical excision, and radiation therapy (RT). Vincristine (VCR) is the main therapy used in treatment of RMS, it is an alkaloid produced from vinca and it is one of the most commonly prescribed drugs in pediatric oncology for the treatment of a number of tumors. Vincristine is FDA-approved for the treatment of a variety of cancers, including ALL, B-cell ALL, lymphoid blast crisis of chronic myeloid leukaemia, neuroblastoma, rhabdomyosarcoma, and Hodgkin and non-Hodgkin lymphomas. Vincristine limits cell growth by preventing mitosis and interrupting microtubule polymerization, As a result, vincristine induces cell cycle arrest and causes apoptosis (cell death) in rapidly dividing cancer cells. The most prevalent side effects of VCR therapy include peripheral neuritis.<br/> The CYP3A5 enzyme is responsible for vincristine metabolism. The effect of CYP3A5 genetic polymorphism on the efficacy and toxicity of VCR on RMS patients still needs further research. Genotyping for CYP3A5 SNPs rs776746, rs10264272 and rs41303343 was performed using Taqman Real- Time PCR assays in a retrospective cohort study of 150 RMS pediatric patients treated with vincristine. The relationship between these genotypes and RMS survival was then examined. We found that patients with CYP3A5*3/*3 had the highest incidence of vincristine-induced neuropathy reaching 61.3%. Patients with CYP3A5*1/*3, CYP3A5*3/*6 and the normal metabolizers with CYP3A5*1/*1 had frequencies of 22%, 10.7%, and 4.7% respectively. Patients with the lowest frequency of 1.3% were those with the CYP3A5*1/*6 genotype.<br/> There was no correlation between the genotypes of CYP3A5*3, CYP3A5*6, CYP3A5*7, and RMS survival. Initial risk, metastasis, response, convulsions, unsteady gait and hepatotoxicity grade had a significant effect on overall survival with p<0.05. CYP3A5*1/*1 have less severe vincristine-induced neuropathy than CYP3A5 *1/*3, CYP3A5 *1/*6 and CYP3A5 *3/*3, CYP3A5 *3/*6. There is a significant influence of CYP3A5 mutation on neuropathy grade and assist of ADL as a part of neurotoxicity.<br/><br/><br/> |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | الساركوما العضلية المخططة (RMS) هو سرطان نادر يتطور في الأنسجة الرخوة، وخاصة أنسجة العضلات الهيكلية وأحيانًا الأعضاء المجوفة مثل المثانة أو الرحم. الساركوما العضلية المخططة مرض غير شائع يمثل 3٪ من جميع الأورام الخبيثة لدى الأطفال. ومع ذلك، فإن الساركوما العضلية المخططة هي الساركوما الأكثر شيوعًا للأنسجة الرخوة لدى الأطفال والمراهقين، حيث تمثل نصف جميع ساركوما الأنسجة الرخوة لدى الأشخاص الذين تقل أعمارهم عن 20 عامًا. يتم علاج معظم مرضى الساركوما العضلية المخططة باستراتيجية متعددة الوسائط تتضمن العلاج الكيميائي والاستئصال الجراحي والعلاج الإشعاعي. فينكريستين (VCR) هو العلاج الرئيسي المستخدم في علاج الساركوما العضلية المخططة، وهو قلويد يتم إنتاجه من نبات الفينكا وهو أحد أكثر الأدوية الموصوفة شيوعًا في طب الأورام للأطفال لعلاج عدد من الأورام. يحد الفينكريستين من نمو الخلايا عن طريق منع الانقسام المتساوي ومقاطعة بلمرة الأنابيب الدقيقة، ونتيجة لذلك، يحفز الفينكريستين توقف دورة الخلية ويسبب موت الخلايا المبرمج في الخلايا السرطانية سريعة الانقسام.<br/>إن إنزيم CYP3A5 مسؤول عن استقلاب الفينكريستين. لا يزال تأثير تعدد الأشكال الجينية لـ CYP3A5 على فعالية وسمية VCR على مرضى RMS بحاجة إلى مزيد من البحث. تم إجراء تحديد النمط الجيني لـ SNPs CYP3A5 rs776746 وrs10264272 وrs41303343 باستخدام اختبارات Taqman Real-Time PCR في دراسة مجموعة استعادية لـ 150 مريضًا من الأطفال المصابين بـ RMS عولجوا بالفينكريستين. ثم تم فحص العلاقة بين هذه الأنماط الجينية وبقاء RMS. وجدنا أن المرضى المصابين بـ CYP3A5 * 3 / * 3 لديهم أعلى معدل للإصابة بالاعتلال العصبي الناجم عن الفينكريستين حيث بلغ 61.3٪. كان لدى المرضى الذين لديهم CYP3A5*1/*3 وCYP3A5*3/*6 والمستقبلين الطبيعيين الذين لديهم CYP3A5*1/*1 ترددات 22% و10.7% و4.7% على التوالي. وكان المرضى الذين لديهم أقل تردد 1.3% هم أولئك الذين لديهم النمط الجيني CYP3A5*1/*6.<br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issued also as CD |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | CYP3A5 |
| -- | SNP |
| -- | Vincristine |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Osama Badary |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hala Fahmy Zaki |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mona Magdy Saber |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Osama Badary |
| -- | Hala Fahmy Zaki |
| -- | Mona Magdy Saber |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology and Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Eman El gebaly |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 14.07.2025 | 91558 | Cai01.08.09.M.Sc.2024.No.C. | 01010110091558000 | 14.07.2025 | 14.07.2025 | Thesis |